These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 29161698)
1. A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. Politaki E; Agelaki S; Apostolaki S; Hatzidaki D; Strati A; Koinis F; Perraki M; Saloustrou G; Stoupis G; Kallergi G; Spiliotaki M; Skaltsi T; Lianidou E; Georgoulias V; Mavroudis D Cell Physiol Biochem; 2017; 44(2):594-606. PubMed ID: 29161698 [TBL] [Abstract][Full Text] [Related]
2. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188 [TBL] [Abstract][Full Text] [Related]
3. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer. Strati A; Kasimir-Bauer S; Markou A; Parisi C; Lianidou ES Breast Cancer Res; 2013 Mar; 15(2):R20. PubMed ID: 23497487 [TBL] [Abstract][Full Text] [Related]
4. Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR. Park HS; Han HJ; Lee S; Kim GM; Park S; Choi YA; Lee JD; Kim GM; Sohn J; Kim SI Yonsei Med J; 2017 Jan; 58(1):19-26. PubMed ID: 27873491 [TBL] [Abstract][Full Text] [Related]
5. Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer. Georgoulias V; Apostolaki S; Bozionelou V; Politaki E; Perraki M; Georgoulia N; Kalbakis K; Kotsakis A; Xyrafas A; Agelaki S; Mavroudis D Cancer Chemother Pharmacol; 2014 Dec; 74(6):1217-25. PubMed ID: 25344760 [TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients. Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361 [TBL] [Abstract][Full Text] [Related]
7. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Chen Y; Zou TN; Wu ZP; Zhou YC; Gu YL; Liu X; Jin CG; Wang XC Int J Biol Markers; 2010; 25(2):59-68. PubMed ID: 20586026 [TBL] [Abstract][Full Text] [Related]
8. Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients. Schindlbeck C; Andergassen U; Hofmann S; Jückstock J; Jeschke U; Sommer H; Friese K; Janni W; Rack B J Cancer Res Clin Oncol; 2013 Jun; 139(6):1055-62. PubMed ID: 23525580 [TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer. Androulakis N; Agelaki S; Perraki M; Apostolaki S; Bozionelou V; Pallis A; Kalbakis K; Xyrafas A; Mavroudis D; Georgoulias V Br J Cancer; 2012 Jun; 106(12):1917-25. PubMed ID: 22669159 [TBL] [Abstract][Full Text] [Related]
10. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126 [TBL] [Abstract][Full Text] [Related]
11. Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success. Ušiaková Z; Mikulová V; Pintérová D; Brychta M; Valchář J; Kubecová M; Tesařová P; Bobek V; Kološtová K In Vivo; 2014; 28(4):605-14. PubMed ID: 24982230 [TBL] [Abstract][Full Text] [Related]
12. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Daskalaki A; Agelaki S; Perraki M; Apostolaki S; Xenidis N; Stathopoulos E; Kontopodis E; Hatzidaki D; Mavroudis D; Georgoulias V Br J Cancer; 2009 Aug; 101(4):589-97. PubMed ID: 19623181 [TBL] [Abstract][Full Text] [Related]
13. Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy. Wang HY; Ahn S; Kim S; Park S; Park S; Han H; Sohn JH; Kim S; Lee H Exp Mol Pathol; 2014 Dec; 97(3):445-52. PubMed ID: 25217799 [TBL] [Abstract][Full Text] [Related]
14. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. Xenidis N; Ignatiadis M; Apostolaki S; Perraki M; Kalbakis K; Agelaki S; Stathopoulos EN; Chlouverakis G; Lianidou E; Kakolyris S; Georgoulias V; Mavroudis D J Clin Oncol; 2009 May; 27(13):2177-84. PubMed ID: 19332733 [TBL] [Abstract][Full Text] [Related]
15. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy. Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991 [TBL] [Abstract][Full Text] [Related]
16. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619 [TBL] [Abstract][Full Text] [Related]
17. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial. Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W; BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743 [TBL] [Abstract][Full Text] [Related]
18. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712 [TBL] [Abstract][Full Text] [Related]
19. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Saloustros E; Perraki M; Apostolaki S; Kallergi G; Xyrafas A; Kalbakis K; Agelaki S; Kalykaki A; Georgoulias V; Mavroudis D Breast Cancer Res; 2011 Jun; 13(3):R60. PubMed ID: 21663668 [TBL] [Abstract][Full Text] [Related]
20. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Bredemeier M; Edimiris P; Tewes M; Mach P; Aktas B; Schellbach D; Wagner J; Kimmig R; Kasimir-Bauer S Oncotarget; 2016 Jul; 7(27):41677-41690. PubMed ID: 27223437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]